Prospective Feasibility Study for Using Cell-Free Circulating Tumor DNA–Guided Therapy in Refractory Metastatic Solid Cancers: An Interim Analysis

PURPOSE: Retrospective studies have demonstrated that cell-free circulating tumor DNA (ctDNA) hotspot testing predicts matched therapy response to first- and second-line therapies in patients with advanced non–small-cell lung cancer (NSCLC). However, no prospective outcomes studies have evaluated ct...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Seung Tae, Banks, Kimberly C., Lee, Se-Hoon, Kim, Kyung, Park, Joon Oh, Park, Se Hoon, Park, Young Suk, Lim, Ho Yeong, Kang, Won Ki, Lanman, Richard B., Talasaz, AmirAli, Park, Keunchil, Lee, Jeeyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2017
Materias:
Original Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446388/
https://www.ncbi.nlm.nih.gov/pubmed/32913970
http://dx.doi.org/10.1200/PO.16.00059

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446388/
https://www.ncbi.nlm.nih.gov/pubmed/32913970
http://dx.doi.org/10.1200/PO.16.00059

Ejemplares similares